Immunovant, Inc. (IMVT)
IMVT moved a median of -0.15% 30 minutes after news, and -0.25% by the close. How IMVT actually reacts to news — the realized, point-in-time move the market made, measured across 346 labeled events over the last three years with zero look-ahead.
IMVT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.04% | 51% | 341 |
| 30-min | -0.15% | 47% | 341 |
| 60-min | -0.27% | 42% | 341 |
| to close | -0.25% | 47% | 346 |
| Middle 50% of IMVT reactions | -1.14% to +0.93% |
|---|---|
| Median reaction (30-min) | -0.15% |
| Measured reactions | 346 |
Half of all Immunovant, Inc. news events land between -1.14% and +0.93% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IMVT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 14 | +0.64% | 71% | +1.16% |
| Coverage initiations | 25 | -0.10% | 48% | -1.61% |
| Rating reiterations | 86 | -0.17% | 42% | -0.58% |
| Price-target raises | 17 | +0.23% | 59% | -0.68% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how IMVT ranks against every other measured name →
That’s how IMVT usually reacts — get an email when it moves on news →Email me when IMVT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMVT's baseline. Nothing else.
Recent IMVT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Immunovant, Inc. (IMVT) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.10% | +0.44% | |
| Bronstein, Gewirtz & Grossman, LLC Initiate an Investigation into Allegations Against Immunovant, Inc. (IMVT) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.25% | -2.29% | |
| IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +0.25% | -2.29% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Immunovant, Inc. (IMVT) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.07% | +0.13% | |
| Immunovant, Inc. (IMVT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.03% | -1.96% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Immunovant, Inc. (IMVT) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.21% | -0.81% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Immunovant, Inc. (IMVT) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.27% | -0.47% | |
| Immunovant, Inc. (IMVT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.06% | +0.43% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Immunovant, Inc. (IMVT) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.08% | +1.76% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Immunovant, Inc. (IMVT) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.36% | +0.18% | |
| Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus | Press release | GlobeNewswire | +0.39% | -4.98% | |
| Form 8-K Immunovant, Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | -0.75% | -0.48% | |
| Form 10-Q Immunovant, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.91% | +4.63% | |
| Form 8-K Immunovant, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.91% | +4.63% | |
| Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 | Press release | GlobeNewswire | +1.91% | +4.63% | |
| Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 | Press release | GlobeNewswire | -0.80% | -0.98% | |
| Form ARS Immunovant, Inc. For: Mar 31 | SEC filing · Form ARS | SEC EDGAR | +1.29% | +2.55% | |
| Form DEF 14A Immunovant, Inc. For: Sep 02 | SEC filing · Form DEF | SEC EDGAR | +1.29% | +2.55% | |
| Form DEFA14A Immunovant, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.29% | +2.55% | |
| Form 10-K Immunovant, Inc. For: Mar 31 | SEC filing · Form 10-K | SEC EDGAR | +4.25% | +17.28% | |
| Form 8-K Immunovant, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +4.25% | +17.28% | |
| Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | Press release | GlobeNewswire | +4.25% | +17.28% | |
| Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 | Press release | GlobeNewswire | -0.82% | -1.95% | |
| Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Press release | GlobeNewswire | -0.90% | +2.08% | |
| Form 10-Q Immunovant, Inc. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.87% | +0.63% | |
| Form 8-K Immunovant, Inc. For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | -4.87% | +0.63% | |
| Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | Press release | GlobeNewswire | -4.87% | +0.63% | |
| Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 | Press release | GlobeNewswire | +0.62% | +3.02% | |
| Form 8-K Immunovant, Inc. For: Dec 10 | SEC filing · Form 8-K | SEC EDGAR | +2.06% | -2.73% | |
| Form 8-K Immunovant, Inc. For: Dec 10 | SEC filing · Form 8-K | SEC EDGAR | +2.86% | +5.75% | |
| Immunovant Announces Pricing of $550 Million Common Stock Financing | Press release | GlobeNewswire | +2.86% | +5.75% | |
| Form 8-K Immunovant, Inc. For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | +0.99% | +1.76% | |
| Form 10-Q Immunovant, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.36% | +2.68% | |
| Form 8-K Immunovant, Inc. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +1.36% | +2.68% | |
| Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 | Press release | GlobeNewswire | +1.36% | +2.68% | |
| Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 | Press release | GlobeNewswire | +0.85% | +3.58% | |
| Form 8-K Immunovant, Inc. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | +1.42% | +7.67% | |
| Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | Press release | GlobeNewswire | +0.55% | +7.81% | |
| Form 8-K Immunovant, Inc. For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | +0.27% | -0.88% | |
| Form 10-Q Immunovant, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.61% | -4.77% | |
| Form 8-K Immunovant, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -1.61% | -4.77% | |
| Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 | Press release | GlobeNewswire | -1.61% | -4.77% | |
| Form 8-K Immunovant, Inc. For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | -0.24% | -1.83% | |
| Improving Clinical Tech Adoption: Site-Centric Approaches, Upcoming Webinar Hosted by Xtalks | Press release | PR Web | +0.49% | -3.14% | |
| Form ARS Immunovant, Inc. For: Mar 31 | SEC filing · Form ARS | SEC EDGAR | -2.31% | +1.10% | |
| Form DEF 14A Immunovant, Inc. For: Aug 27 | SEC filing · Form DEF | SEC EDGAR | -2.31% | +1.10% | |
| Form DEFA14A Immunovant, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -2.31% | +1.10% | |
| Form 10-K Immunovant, Inc. For: Mar 31 | SEC filing · Form 10-K | SEC EDGAR | -0.07% | +0.95% | |
| Form 8-K Immunovant, Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -0.07% | +0.95% | |
| Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Press release | GlobeNewswire | -0.07% | +0.95% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMVT section they belong to.
Where else IMVT is measured.
IMVT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Immunovant, Inc.'s median reaction calculated?
Every labeled IMVT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 346 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of IMVT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMVT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.